Eliprodil

Clinical data
ATC code	None
Identifiers
IUPAC name 1-(4-Chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
CAS Number	119431-25-3 N
PubChemCID	60703
ChemSpider	54708 Y
UNII	YW62A6TW29
ChEBI	CHEBI:91784
ChEMBL	ChEMBL28564 Y
CompTox Dashboard(EPA)	DTXSID1045744
ECHA InfoCard	100.162.249
Chemical and physical data
Formula	C20H23ClFNO
Molar mass	347.86 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O
InChI InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2 Y Key:GGUSQTSTQSHJAH-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Eliprodil (codenamed SL-82.0715) is an NMDA antagonist drug candidate which selectively inhibits the NR2B (GLUN2B) subtype NMDA receptor at submicromolar concentrations. Eliprodil failed a Phase III clinical trial for the treatment of acute ischemic stroke in 1996, sponsored by Synthélabo Recherche.^[1][2][3]

NMDA receptors are a key component in mediating glutamate-induced excitotoxicity, and it is believed that NMDA antagonists would be neuroprotective after a stroke or other traumatic brain injury.^[4] After a traumatic brain injury, neurons become deprived of glucose and oxygen. These neurons quickly lose ATP and become depolarized, which releases glutamate. The extracellular buildup of glutamate triggers the overstimulation of AMPA and NMDA receptors. This, in turn, causes an influx of Na⁺ and Ca²⁺. Therefore, when NMDA receptors are activated, there is an increase in intracellular Ca²⁺ concentration. High Ca²⁺ causes fatal metabolic consequences, including neuronal cell death.^[3]